Form 4: Nuvalent CLO Sells Shares, Receives New Equity Awards

Nuvalent's Chief Legal Officer, Deborah Ann Miller, reported sales of Class A Common Stock to cover tax obligations and the acquisition of new restricted stock units and stock options.

Summary

• Deborah Ann Miller, Chief Legal Officer of Nuvalent, Inc. (NUVL), reported transactions involving the company's Class A Common Stock.
• Miller sold a total of 5,779 shares of Class A Common Stock across multiple transactions on January 5 and January 6, 2026.
• The sales were executed at weighted average prices ranging from $96.06 to $98.52 per share.
• These sales were pre-planned under a Rule 10b5-1 instruction letter, entered into on December 6, 2023, to satisfy tax withholding obligations upon the vesting of previously granted equity awards.
• On January 7, 2026, Miller acquired 17,500 shares of Class A Common Stock through Restricted Stock Units (RSUs) at a price of $0.00.
• The RSUs are scheduled to vest in three equal annual installments following January 7, 2026, contingent on continued service.
• Also on January 7, 2026, Miller acquired stock options for 17,500 shares of Class A Common Stock with an exercise price of $106.82.
• These stock options will vest over four years following January 7, 2026, in equal monthly installments, subject to continued service.
• Following these transactions, Miller's direct beneficial ownership of Class A Common Stock is 59,634 shares, and direct beneficial ownership of stock options is 17,500 shares.

Sentiment

Score: 7

Explanation: The filing reports routine insider transactions, including sales to cover tax obligations from vested equity awards and the grant of new equity compensation (RSUs and stock options). The new equity grants indicate continued alignment of management's interests with shareholders, slightly outweighing the routine tax-related sales.

Positives

• The acquisition of 17,500 Restricted Stock Units (RSUs) and 17,500 stock options indicates continued equity compensation and alignment of the Chief Legal Officer's interests with long-term shareholder value.
• The vesting schedules for both RSUs (three equal annual installments) and stock options (equal monthly installments over four years) incentivize long-term commitment to the company.

Negatives

• The sale of 5,779 shares of Class A Common Stock, even for tax purposes, reduces the direct equity stake of a key executive.

Future Outlook

The acquired Restricted Stock Units (RSUs) are set to vest in three equal annual installments following January 7, 2026. The acquired stock options will vest over four years following January 7, 2026, in equal monthly installments. Both are subject to continued service to Nuvalent, Inc. through the applicable vesting dates.

Management Comments

• The sale was effected pursuant to a durable Rule 10b5-1 sell-to-cover instruction letter entered into on December 6, 2023, to satisfy the reporting person's tax withholding obligations upon the vesting of previously granted equity awards.

Industry Context

This Form 4 filing details routine insider transactions for an executive, which are common in publicly traded companies. The 'sell-to-cover' mechanism for tax obligations upon equity award vesting is a standard practice across industries, particularly in high-growth sectors like biotechnology where equity compensation is a significant component of executive pay. The grant of new RSUs and stock options is also a typical part of executive compensation packages, designed to align management incentives with shareholder interests over the long term.

Comparison to Industry Standards

• The 'sell-to-cover' transaction to satisfy tax withholding obligations upon equity award vesting is a widely accepted and common practice among executives in public companies, including those in the biotechnology sector like Nuvalent. This mechanism is standard for managing tax liabilities associated with equity compensation.
• The grant of Restricted Stock Units (RSUs) and stock options as part of executive compensation is a prevalent industry standard, particularly in growth-oriented companies. This structure is designed to incentivize long-term performance and retention, aligning executive interests with shareholder value creation, similar to practices observed at comparable biotech firms.

Stakeholder Impact

• Shareholders: The transactions represent routine executive compensation and tax management. The new equity grants align the Chief Legal Officer's long-term interests with shareholder value, while the sales are not indicative of a change in company outlook.
• Employees: No direct impact on the broader employee base is indicated, beyond the reporting person's compensation.

Next Steps

• RSUs will vest in three equal annual installments following January 7, 2026, subject to continued service.
• Stock options will vest over four years following January 7, 2026, in equal monthly installments, subject to continued service.

Key Dates

Recommendation

This Form 4 details routine insider transactions for Nuvalent's Chief Legal Officer, Deborah Ann Miller. The sales were pre-planned 'sell-to-cover' transactions to satisfy tax obligations upon the vesting of prior equity awards, which is a common and expected event for executives. Simultaneously, Miller received new equity compensation in the form of Restricted Stock Units and stock options, demonstrating continued alignment of her interests with the company's long-term performance. These transactions do not signal any fundamental change in the company's prospects or management's confidence, thus a 'hold' recommendation is appropriate as the filing itself provides no new information to alter an existing investment thesis.

Keywords

Nuvalent, NUVL, Form 4, Insider Trading, Equity Awards, Restricted Stock Units, Stock Options, Deborah Ann Miller, Chief Legal Officer, 10b5-1 Plan